WuXi PharmaTech plans to continue its growth by expanding into biotech, safety evaluation and manufacturing. In fact, to make the growth a reality, the company invests about $60 million each year in capital expenditures. "The majority of our clients are big international firms, with Pfizer and Merck ranking as the top two,” said Edward Hu, COO of the WuXi PharmaTech in a recent interview. More details...

Stock Symbol: (NYSE: WX)